Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and tolerability of tapentadol for the treatment of chronic low back pain in elderly patients

  • Original Article
  • Published:
Aging Clinical and Experimental Research Aims and scope Submit manuscript

Abstract

Background

Chronic low back pain (CLBP) is a highly prevalent and disabling condition in the elderly, and yet it is undertreated and understudied in this patient population. Tapentadol is a central analgesic with an improved tolerability profile that may be particularly beneficial to the elderly CLBP.

Methods

We performed an observational retrospective study to comparatively assess the efficacy and tolerability of tapentadol in young and elderly patients with severe CLBP. Sixtyfive young patients (< 65 years) and 87 elderly patients (≥ 65 years) were titrated on tapentadol extended release to their optimal dose (25–250 mg bid) over 1 month and, then, maintained at that dose for 3 months. The primary endpoint were changes from baseline in 24-h pain intensity on a 0–10 Numerical Rating Scale (NRS) at month-4 of treatment (titration plus maintenance periods). Patients were assessed for several efficacy and tolerability outcomes using a battery of scales and tests for neuropathic pain intensity, quality of life and sleep, and cognitive and gastrointestinal functions.

Results

At pretreatment, young and elderly patients had similar pain intensities with younger patients presenting with more intense depressive and neuropathic pain symptoms, and lesser comorbidities and durations of pain (P < 0.05). Thirty-eight patients discontinued treatment because of adverse events occurring mostly during titration. Treatment with tapentadol was associated with comparable and clinically meaningful pain reductions in 24-h NRS from baseline to treatment month-4 both in young and elderly patients (− 5.3 ± 1.4 and – 4.8 ± 2.1; P < 0.01); a 50% pain relief was achieved in 66% and 58% of young and elderly patients. The percentage of patients with a neuropathic component decreased similarly in young and elderly patients (from 38 to 0% and from 19 to 3%; P < 0.01). Quality of life and sleep improved. The performances in global cognition and sustained attention tasks remained stable or improved across all age group.

Conclusions

These findings indicate that tapentadol extended release maintains efficacy and good tolerability in CLBP patients with advancing age.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Vos T, Flaxman AD, Naghavi M et al (2012) Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2163–2196

    PubMed  PubMed Central  Google Scholar 

  2. Global Industry Analysts, Inc. Report (2011) https://www.prweb.com/pdfdownload/8052240.pdf. Accessed 6 June 2017

  3. Thomas E, Peat G, Harris L et al (2004) The prevalence of pain and pain interference in a general population of older adults: cross-sectional findings from the north Staffordshire osteoarthritis project (NorStOP). Pain 110:361–368

    PubMed  Google Scholar 

  4. Papageorgiou AC, Croft PR, Ferry S et al (1995) Estimating the prevalence of low back pain in the general population: evidence from the south Manchester back pain survey. Spine 20:1889–1994

    CAS  PubMed  Google Scholar 

  5. Palacios-Ceña D, Alonso-Blanco C, Hernández-Barrera V et al (2015) Prevalence of neck and low back pain in community-dwelling adults in Spain: an updated population-based national study. Eur Spine J 24:482–492

    PubMed  Google Scholar 

  6. Fernández-de-las-Peñas C, Alonso-Blanco C, Hernández-Barrera V et al (2013) Has the prevalence of neck pain and low back pain changed over the last 5 years? A population-based national study in Spain. Spine J 13:1069–1076

    PubMed  Google Scholar 

  7. Noormohammadpour P, Mansournia MA, Koohpayehzadeh J et al (2017) Prevalence of chronic neck pain, low back pain, and knee pain and their related factors in community-dwelling adults in Iran: a population-based national study. Clin J Pain 33:181–187

    PubMed  Google Scholar 

  8. Wong AY, Karppinen J, Samartzis D (2017) Low back pain in older adults: risk factors, management options and future directions. Scoliosis Spinal Disord 18:12–14

    Google Scholar 

  9. Podichetty VK, Mazanec DJ, Biscup RS (2003) Chronic non-malignant musculoskeletal pain in older adults: clinical issues and opioid intervention. Postgrad Med J 79:627–633

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Herr KA, Garand L (2011) Assessment and measurement of pain in older adults. Clin Geriatr Med 17:457–478

    Google Scholar 

  11. Taverner T (2005) The evidence on perceptions of pain in older people. Nurs Times 101:36–38

    PubMed  Google Scholar 

  12. Amaral G, Martins H, Silva AG (2018) Postural control in subclinical neck pain: a comparative study on the effect of pain and measurement procedures. Scand J Pain 18:295–302

    PubMed  Google Scholar 

  13. Landis CA (2015) Sleep and pain: milestones and advances from research. In: Chokroverty S, Billiard M (eds) Sleep medicine. A comprehensive guide to its development, clinical milestones, and advances in treatment. Springer, New York, pp 433–522

    Google Scholar 

  14. Uchmanowicz I, Kołtuniuk A, Stępień A et al (2018) The influence of sleep disorders on the quality of life in patients with chronic low back pain. Scand J Caring Sci 16:119–127

    Google Scholar 

  15. Park SM, Kim HJ, Jang S et al (2018) Depression is closely associated with chronic low back pain in patients over 50 years of age: a cross-sectional study using the sixth Korea national health and nutrition examination survey (KNHANES VI-2). Spine (Phila Pa 1976) 43:1281–1288

    Google Scholar 

  16. Rowe JW, Andres R, Tobin JD et al (1976) The effect of age in creatinine clearance in man: a cross sectional and longitudinal study. J Gerontol 31:155–163

    CAS  PubMed  Google Scholar 

  17. Weil AJ, Masters ET, Barsdorf AI et al (2017) Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe chronic low back pain. Health Qual Life Outcomes 15:202

    PubMed  PubMed Central  Google Scholar 

  18. Christoph A, Eerdekens MH, Kok M et al (2017) Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial. Pain 158:1813–1824

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Gimbel J, Spierings EL, Katz N et al (2016) Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a phase 3, enriched enrollment, randomized withdrawal study. Pain 157:2517–2526

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Markman J, Gudin J, Rauck R et al (2017) Efficacy, safety, and tolerability of NKTR-181 in patients with moderate to severe chronic low-back pain: a phase 3 study. PAINWeek, 5–9 September; Las Vegas, Nevada. Abstract 41

  21. Azzam AAH, McDonald J, Lambert DG (2019) Hot topics in opioid pharmacology: mixed and biased opioids. Br J Anaesth 122:e136–e145

    CAS  PubMed  Google Scholar 

  22. Electronic Medicines Compendium (2018) Palexia SR prolonged release tablets. Summary of product characteristics. Last updated on January 3, 2018. https://www.medicines.org.uk/emc/medicine/28373. Accessed 11 May 2020

  23. Lange B, Sohns M, Tempero J et al (2018) Efficacy and safety of tapentadol prolonged release formulation in the treatment of elderly patients with moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo-, and active-controlled trials. Curr Med Res Opin 34:2113–2123

    CAS  PubMed  Google Scholar 

  24. Freo U, Romualdi P, Kress HG (2019) Tapentadol for neuropathic pain: a review of clinical studies. J Pain Res 12:1537–1551

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Coluzzi F, Polati E, Freo U et al (2019) Tapentadol: an effective option for the treatment of back pain. J Pain Res 12:1521–1528

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Freynhagen R, Baron R, Gockel U et al (2006) PainDetect: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 22:1911–1912

    PubMed  Google Scholar 

  27. Kodraliu G, Mosconi P, Groth N et al (2001) Subjective health status assessment: evaluation of the Italian version of the SF-12 Health Survey. Results from the MiOS Project. J Epidemiol Biostat 6:305–316

    CAS  PubMed  Google Scholar 

  28. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198

    CAS  PubMed  Google Scholar 

  29. Wechsler D (1981) Manual for the Wechsler adult intelligence scale, revised. Psychological Corporation, New York

    Google Scholar 

  30. Lezak MD (1983) Neuropsychological Assessment, 2nd edn. Oxford University Press, New York

    Google Scholar 

  31. Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370

    CAS  PubMed  Google Scholar 

  32. Rentz AM, Yu R, Müller-Lissner S et al (2009) Validation of the Bowel function index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ 12:371–383

    CAS  PubMed  Google Scholar 

  33. Naples JG, Gellad WF, Hanlon JT (2016) The role of opioid analgesics in geriatric pain management. Clin Geriatr Med 32:725–735

    PubMed  PubMed Central  Google Scholar 

  34. Mercadante S, Ferrera P, Villari P et al (2006) Opioid escalation in patients with cancer pain: the effect of age. J Pain Symptom Manage 32:413–419

    CAS  PubMed  Google Scholar 

  35. Guerriero F, Roberto A, Greco MT et al (2016) Long-term efficacy and safety of oxycodone–naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study. Drug Des Devel Ther 10:1515–1523

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Ali A, Arif AW, Bhan C et al (2018) Managing chronic pain in the elderly: an overview of the recent therapeutic advancements. Cureus 10:e3293

    PubMed  PubMed Central  Google Scholar 

  37. Abdulla A, Adams N, Bone M et al (2013) British Geriatric Society. Guidance on the management of pain in older people. Age Ageing 42S1:i 1–I 57

    Google Scholar 

  38. Barber JB, Gibson SJ (2009) Treatment of chronic non-malignant pain in the elderly: safety considerations. Drug Saf 32:457–474

    CAS  PubMed  Google Scholar 

  39. American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons (2009) Pharmacological management of persistent pain in older persons. Pain Med 10:1062–1083

    Google Scholar 

  40. Galicia-Castillo M (2016) Opioids for persistent pain in older adults. Cleve Clin J Med 83:443–451

    PubMed  Google Scholar 

  41. Crockett SD, Greer KB, Heidelbaugh JJ et al (2019) American Gastroenterological Association Institute guideline on the medical management of opioid-induced constipation. Gastroenterology 156:218–226

    PubMed  Google Scholar 

  42. Moriarty O, Ruane N, O’gorman D et al (2017) Cognitive impairment in patients with chronic neuropathic or radicular pain: an interaction of pain and age. Front Behav Neurosci 11:100

    PubMed  PubMed Central  Google Scholar 

  43. Berryman C, Stanton TR, Jane Bowering K et al (2013) Evidence for working memory deficits in chronic pain: a systematic review and meta-analysis. Pain 154:1181–1196

    PubMed  Google Scholar 

  44. Whitlock EL, Diaz-Ramirez LG, Glymour MM et al (2017) Association between persistent pain and memory decline and dementia in a longitudinal cohort of elders. JAMA Intern Med 177:1146–1153

    PubMed  PubMed Central  Google Scholar 

  45. Freo U, Furnari M, Ori C (2018) Effects of tapentadol on pain, motor symptoms and cognitive functions in Parkinson's disease. J Pain Res 13:1849–1856

    Google Scholar 

  46. Kvitting AS, Fällman K, Wressle E et al (2019) Age-normative MMSE data for older persons aged 85 to 93 in a longitudinal swedish cohort. J Am Geriatr Soc 67:534–538

    PubMed  Google Scholar 

  47. Kulisevsky J, Pagonabarraga J (2009) Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment. Mov Disord 24:1103–1110. https://doi.org/10.1002/mds.22506

    Article  PubMed  Google Scholar 

  48. Hoops S, Nazem S, Siderowf AD et al (2009) Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 73:1738–1745

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Tombaugh TN (2004) Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol 19:203–214

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Anesthesiology and Intensive Medicine, Department of Medicine-DIMED, Padua University, Via Giustiniani 2, 35128, Padua, Italy

    Ulderico Freo, Maurizio Furnari, Francesco Ambrosio & Paolo Navalesi

Authors
  1. Ulderico Freo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maurizio Furnari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francesco Ambrosio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paolo Navalesi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulderico Freo.

Ethics declarations

Conflict of interest

The authors have nothing to disclose.

Ethical approval

All procedures were carried out in accordance with the ethical standards with the 1964 Helskinki declariation on human clinical studies. The study hypotheses, outcomes measures, and protocol were approved by our IRB (Comitato Etico per la Sperimentazione Clinica della Provincia di Padova).

Informed consent

All patients signed an informed consent.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Freo, U., Furnari, M., Ambrosio, F. et al. Efficacy and tolerability of tapentadol for the treatment of chronic low back pain in elderly patients. Aging Clin Exp Res 33, 973–982 (2021). https://doi.org/10.1007/s40520-020-01586-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40520-020-01586-0

Keywords

Search

Navigation